A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related

Inclusion Criteria:

• Histologically or cytologically confirmed Hepatocellular carcinoma (HCC)

• Subjects with HCC who have received standard systemic therapies

• HLA-A *02

• BCLC stage B or C

• Child-pugh score ≤ 7 ol

• Serum HBeAg negative, serum (or tumor tissue) HBsAg positive, and serum HBV-DNA mustbe ≤ 1 × 1000 IU/ml

• Have at least one measurable leasion at baseline as per mRECIST and iRECIST

• Life expectancy of 3 months or greater

• The organ function is in good condition.

Exclusion Criteria:

• Subjects with history of another primary cancer within 5 years

• Central nervous system metastasis and clinically significant central nervous systemdisease

• Previous or current coexistence of hepatic encephalopathy

• Currently present with symptomatic third space fluid accumulation

• Hypertension that is poorly controlled, as determined by researchers (i.e., arterialhypertension that remains uncontrolled despite standard treatment)

• Known history of neurological or mental disorder, including epilepsy or dementia

• Suffering from active autoimmune diseases, or other significant ongoing immunerejection based on pathology and clinical diagnosis

• Prior exposure to any cell therapy such as, but not limited to killer (NK) cells,cytokine-induced killer (CIK) cells, dendritic cells (DC), cytotoxic T lymphocytes (CTL), stem cell therapy

• Positive for HCV - RNA test or positive for HAV IgM antibody or positive for HDV IgMantibody; or there is current evidence indicating the presence of HEV infection

• Allergy to immunotherapy drugs and lymphodepleting chemotherapy (cyclophosphamideand fludarabine)

• Any condition which, in the investigator's opinion, makes the subject unsuitable fortrial participation